VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Breast Cancer MORE >>

In patients with HER2-positive early breast cancer, 6 months of adjuvant treatment with trastuzumab (Herceptin) was noninferior for disease-free survival compared with the standard 12-month schedule, according to findings from the phase III PERSEPHONE trial presented ahead of the 2018 ASCO Annual Meeting.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.